Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers
Seeking Alpha News (Mon, 22-Apr 10:01 AM ET)
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer
TipRanks (Mon, 22-Apr 7:25 AM ET)
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Globe Newswire (Fri, 5-Apr 8:04 AM ET)
Globe Newswire (Fri, 5-Apr 8:02 AM ET)
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Globe Newswire (Fri, 5-Apr 8:00 AM ET)
Globe Newswire (Wed, 13-Mar 8:00 AM ET)
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Globe Newswire (Wed, 28-Feb 8:00 AM ET)
Protara Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 31-Jan 7:30 AM ET)
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Protara Therapeutics trades on the NASDAQ stock market under the symbol TARA.
As of April 24, 2024, TARA stock price declined to $2.82 with 422,076 million shares trading.
TARA has a beta of 2.41, meaning it tends to be more sensitive to market movements. TARA has a correlation of 0.13 to the broad based SPY ETF.
TARA has a market cap of $32.24 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, TARA stock traded as high as $12.33 and as low as $1.04.
The top ETF exchange traded funds that TARA belongs to (by Net Assets): VTI, VXF, IWC, DFSU.
TARA has underperformed the market in the last year with a price return of -19.7% while the SPY ETF gained +24.2%. However, in the short term, TARA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +43.9% vs +4.6% return in SPY. But in the last 2 weeks, TARA shares have been beat by the market, returning -12.4% compared to an SPY return of -2.7%.
TARA support price is $2.81 and resistance is $3.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TARA stock will trade within this expected range on the day.